Literature DB >> 24778322

Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance.

Uzoma K Iheagwara1, Pamela L Beatty, Phu T Van, Ted M Ross, Jonathan S Minden, Olivera J Finn.   

Abstract

Most tumor-associated antigens (TAA) are self-molecules that are abnormally expressed in cancer cells and become targets of antitumor immune responses. Antibodies and T cells specific for some TAAs have been found in healthy individuals and are associated with lowered lifetime risk for developing cancer. Lower risk for cancer has also been associated with a history of febrile viral diseases. We hypothesized that virus infections could lead to transient expression of abnormal forms of self-molecules, some of which are TAAs; facilitated by the adjuvant effects of infection and inflammation, these molecules could elicit specific antibodies, T cells, and lasting immune memory simultaneously with immunity against viral antigens. Such infection-induced immune memory for TAA would be expected to provide life-long immune surveillance of cancer. Using influenza virus infection in mice as a model system, we tested this hypothesis and demonstrated that influenza-experienced mice control 3LL mouse lung tumor challenge better than infection-naive control mice. Using 2D-difference gel electrophoresis and mass spectrometry, we identified numerous molecules, some of which are known TAAs, on the 3LL tumor cells recognized by antibodies elicited by two successive influenza infections. We studied in detail immune responses against glyceraldehyde-3-phosphate dehydrogenase (GAPDH), histone H4, HSP90, malate dehydrogenase 2, and annexin A2, all of which were overexpressed in influenza-infected lungs and in tumor cells. Finally, we show that immune responses generated through vaccination against peptides derived from these antigens correlated with improved tumor control. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24778322      PMCID: PMC4006373          DOI: 10.1158/2326-6066.CIR-13-0125

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  50 in total

Review 1.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

2.  Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.

Authors:  Manimalha Balasubramani; Chitose Nakao; Guy T Uechi; John Cardamone; Kathy Kamath; Kristen L Leslie; Raghavan Balachandran; Leslie Wilson; Billy W Day; Mary Ann Jordan
Journal:  Mutat Res       Date:  2010-09-09       Impact factor: 2.433

3.  High HSP90 expression is associated with decreased survival in breast cancer.

Authors:  Elah Pick; Yuval Kluger; Jennifer M Giltnane; Christopher Moeder; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

4.  The role of annexin A2 in tumorigenesis and cancer progression.

Authors:  Noor A Lokman; Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Cancer Microenviron       Date:  2011-03-05

5.  Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells.

Authors:  Michael S Turner; Patrice A Cohen; Olivera J Finn
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

6.  T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.

Authors:  Hiroyuki Suzuki; Daniel F Graziano; John McKolanis; Olivera J Finn
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

7.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

Review 8.  Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Authors:  F Pagès; J Galon; M-C Dieu-Nosjean; E Tartour; C Sautès-Fridman; W-H Fridman
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

9.  Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma.

Authors:  N Schek; B L Hall; O J Finn
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

Review 10.  Acute infections as a means of cancer prevention: opposing effects to chronic infections?

Authors:  Stephen A Hoption Cann; J P van Netten; C van Netten
Journal:  Cancer Detect Prev       Date:  2006-02-21
View more
  17 in total

Review 1.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.

Authors:  Camille Jacqueline; Olivera J Finn
Journal:  Semin Immunol       Date:  2020-04-06       Impact factor: 11.130

3.  Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death.

Authors:  Frederick J Kohlhapp; Erica J Huelsmann; Andrew T Lacek; Jason M Schenkel; Jevgenijs Lusciks; Joseph R Broucek; Josef W Goldufsky; Tasha Hughes; Janet P Zayas; Hubert Dolubizno; Ryan T Sowell; Regina Kühner; Sarah Burd; John C Kubasiak; Arman Nabatiyan; Sh'Rae Marshall; Praveen K Bommareddy; Shengguo Li; Jenna H Newman; Claude E Monken; Sasha H Shafikhani; Amanda L Marzo; Jose A Guevara-Patino; Ahmed Lasfar; Paul G Thomas; Edmund C Lattime; Howard L Kaufman; Andrew Zloza
Journal:  Cell Rep       Date:  2016-10-18       Impact factor: 9.423

4.  Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients.

Authors:  Amanda M Lulu; Kara L Cummings; Erin D Jeffery; Paisley T Myers; Dennis Underwood; Rachel M Lacy; Kimberly A Chianese-Bullock; Craig L Slingluff; Susan C Modesitt; Victor H Engelhard
Journal:  Cancer Immunol Res       Date:  2021-08-19       Impact factor: 11.151

5.  Cancer Microbiology.

Authors:  Daniel DiMaio; Brinda Emu; Andrew L Goodman; Walther Mothes; Amy Justice
Journal:  J Natl Cancer Inst       Date:  2022-05-09       Impact factor: 11.816

6.  Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention.

Authors:  Camille Jacqueline; Amanda Lee; Nolan Frey; Jonathan S Minden; Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2020-05-28       Impact factor: 11.151

Review 7.  Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic.

Authors:  Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2014-08       Impact factor: 11.151

Review 8.  Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunities.

Authors:  Camille Jacqueline; Nathalie Bonnefoy; Guillaume M Charrière; Frédéric Thomas; Benjamin Roche
Journal:  Oncoimmunology       Date:  2018-06-11       Impact factor: 8.110

9.  Precancer Atlas to Drive Precision Prevention Trials.

Authors:  Avrum Spira; Matthew B Yurgelun; Ludmil Alexandrov; Anjana Rao; Rafael Bejar; Kornelia Polyak; Marios Giannakis; Ali Shilatifard; Olivera J Finn; Madhav Dhodapkar; Neil E Kay; Esteban Braggio; Eduardo Vilar; Sarah A Mazzilli; Timothy R Rebbeck; Judy E Garber; Victor E Velculescu; Mary L Disis; Douglas C Wallace; Scott M Lippman
Journal:  Cancer Res       Date:  2017-04-01       Impact factor: 13.312

10.  Infections and cancer: the "fifty shades of immunity" hypothesis.

Authors:  Camille Jacqueline; Aurélie Tasiemski; Gabriele Sorci; Beata Ujvari; Fatima Maachi; Dorothée Missé; François Renaud; Paul Ewald; Frédéric Thomas; Benjamin Roche
Journal:  BMC Cancer       Date:  2017-04-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.